Case Report: Integrated echocardiographic assessment guided Liwen procedure for treating obstructive hypertrophic cardiomyopathy with ventricular aneurysm.
contrast-enhanced echocardiography
hypertrophic cardiomyopathy
hypertrophic obstructive cardiomyopathy
speckle tracking echocardiography
transthoracic echocardiography
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
08
2023
accepted:
13
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disease, with an estimated incidence of 0.2%-6%, and is the main cause of sudden cardiac death (SCD) in young athletes. Left ventricular apical aneurysm (LVAA) is a rare subtype of HCM, accounting for about 5% of HCM patients, and has a higher incidence of cardiovascular adverse events. In cases of hypertrophic obstructive cardiomyopathy with LVAA (HOCM-LVAA) that do not respond adequately to optimized medical therapy, the echocardiography-guided percutaneous intra-myocardial septal radiofrequency ablation (PIMSRA, Liwen procedure) emerges as a promising and effective novel therapeutic approach. In this case report, we present for the first time a comprehensive application of echocardiographic techniques, including TTE, 2-D STE, and contrast enhancement, in the diagnosis, treatment, surgical guidance, and assessment of therapeutic outcomes in a case of HOCM-LVAA.
Identifiants
pubmed: 38028451
doi: 10.3389/fcvm.2023.1278457
pmc: PMC10646534
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1278457Informations de copyright
© 2023 Zhang, Zhao, Wang, Qin, Wang and Chu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Med. 2023 Apr 11;12(8):
pubmed: 37109147
Mol Genet Metab. 2006 Feb;87(2):169-74
pubmed: 16236538
Heart. 2023 Jan 27;109(4):289-296
pubmed: 36270787
J Am Coll Cardiol. 2017 Feb 21;69(7):761-773
pubmed: 28209216
J Am Coll Cardiol. 2015 Mar 31;65(12):1249-1254
pubmed: 25814232
Circulation. 1995 Aug 15;92(4):785-9
pubmed: 7641357
J Am Coll Cardiol. 2018 Oct 16;72(16):1898-1909
pubmed: 30309466
ESC Heart Fail. 2023 Jun;10(3):1570-1579
pubmed: 36637048
J Interv Cardiol. 2021 Feb 10;2021:1905184
pubmed: 33628143
Front Cardiovasc Med. 2022 Nov 09;9:1028763
pubmed: 36440055
Circulation. 2020 Dec 22;142(25):e533-e557
pubmed: 33215938
Circulation. 2009 Jun 9;119(22):e557; author reply e558
pubmed: 19506120
Echocardiography. 2018 Aug;35(8):1230-1232
pubmed: 29870575
Int J Angiol. 2020 Sep;29(3):180-182
pubmed: 32904728
Heart Fail Rev. 2019 May;24(3):359-366
pubmed: 30617667